Drug Search Results
More Filters [+]

Efavirenz

Alternative Names: efavirenz, sustiva, stocrin, atripla, symfi, symfi lo
Latest Update: 2024-08-08
Latest Update Note: News Article

Product Description

Efavirenz is used along with other medications to treat human immunodeficiency virus (HIV) infection. Efavirenz is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although efavirenz does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.  (Sourced from: https://medlineplus.gov/druginfo/meds/a699004.html)

Mechanisms of Action: NNRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: HIV Infections

Known Adverse Events: Dizziness

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Efavirenz

Countries in Clinic: Australia, Burkina Faso, Cameroon, China, Czech Republic, France, Ivory Coast, Netherlands, New Zealand, Poland, United Kingdom, United States

Active Clinical Trial Count: 11

Highest Development Phases

Phase 3: HIV Infections

Phase 1: Breast Cancer|Fallopian Tube Cancer|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Lymphoma, B-Cell|Malaria|Oncology Solid Tumor Unspecified|Oncology Unspecified|Ovarian Cancer|Peritoneal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MODERATO

P3

Active, not recruiting

HIV Infections

2025-02-05

CTR20222508

P1

Completed

Lymphoma, B-Cell

2023-01-27

SHR1459-I-110

P1

Completed

Healthy Volunteers|Oncology Unspecified

2022-12-02

39%

SHR1459-I-110

P1

Completed

Healthy Volunteers|Oncology Unspecified

2022-12-02

39%

CKAF156A2107

P1

Completed

Malaria

2022-11-22

21%

CKAF156A2107

P1

Completed

Malaria

2022-11-22

21%

Recent News Events